Diadem is a diagnostic company developing a blood‑based test that detects a specific conformation of the p53 protein to predict early onset of Alzheimer’s disease. The proprietary AlzoSure™ assay provides a non‑invasive, cost‑effective tool for diagnosing patients and improving recruitment for Alzheimer’s drug trials, with pilot studies showing predictive capability for cognitive decline.
Funding
$2.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Alzheimer’s disease often remains undiagnosed until significant cognitive decline occurs, and existing diagnostic methods are invasive, costly, and require specialized equipment, limiting early detection and timely intervention.
Solution
Diadem offers a blood‑based diagnostic platform that detects a disease‑specific conformation of the p53 protein using a proprietary antibody. The AlzoSure™ assay provides a minimally invasive, cost‑effective test that can identify individuals at risk of developing Alzheimer’s disease before clinical symptoms appear. By delivering quantitative risk scores, the test supports clinicians in early diagnosis, patient monitoring, and stratification for clinical trial enrollment. The platform integrates with standard laboratory workflows and transmits results securely to healthcare providers for interpretation.
Target Audience
Primary customers are neurologists, memory‑clinic physicians, and clinical trial sponsors seeking early, non‑invasive biomarkers for Alzheimer’s disease diagnosis and patient recruitment.
Features
- Proprietary monoclonal antibody targeting a unique p53 protein conformation linked to early Alzheimer’s pathology
- Fully automated ELISA‑type assay compatible with routine clinical laboratory equipment
- Quantitative risk assessment reported as a predictive score for cognitive decline
- Validated in pilot clinical studies showing ability to predict progression several years before diagnosis
- Enables efficient patient selection and enrollment for Alzheimer’s drug trials
- Secure, cloud‑based result delivery with integration options for electronic health record systems